-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on Kestra Medical Techs, Lowers Price Target to $23

Benzinga·04/16/2025 16:03:52
Listen to the news
Goldman Sachs analyst David Roman maintains Kestra Medical Techs (NASDAQ:KMTS) with a Neutral and lowers the price target from $24 to $23.